Workflow
Realcan(002589)
icon
Search documents
瑞康医药(002589) - 2025 Q2 - 季度财报
2025-08-25 13:05
瑞康医药集团股份有限公司 2025 年半年度报告全文 2025 年半年度报告 2025 年 8 月 1 瑞康医药集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担 个别和连带的法律责任。 公司负责人韩旭、主管会计工作负责人冯芸及会计机构负责人(会计主管 人员)曹庆岩声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 可能存在行业竞争、经营与管理、市场、国家政策等风险,敬请广大投 资者注意投资风险。 公司计划不派发现金红利,不送红股,不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 6 | | | 第三节 | 管理层讨论与分析 9 | | | 第四节 | 公司治理、环境和社会 | 22 | | 第五节 | 重要事项 | 27 | | 第六节 | 股份变动及股东情况 33 | | | 第七节 | 债券相关情 ...
瑞康医药:截至2025年8月10日,公司股东总数为72251户
Zheng Quan Ri Bao· 2025-08-18 11:11
Group 1 - The company, Ruikang Pharmaceutical, stated that as of August 10, 2025, the total number of shareholders is 72,251 [2]
瑞康医药董秘李喆留置变更为责令候查
Zhong Guo Jing Ji Wang· 2025-08-15 07:45
中国经济网北京8月15日讯(记者郭文培)8月13日,瑞康医药(002589)集团股份有限公司(以下简称瑞康 医药)披露公告称,公司收到济南市济阳区监察委员会签发的《变更留置通知书》,济南市济阳区监察 委员会已解除对公司董事、董事会秘书及副总裁李喆的留置措施,变更为责令候查措施。 根据瑞康医药此前公告,李喆1986年出生,硕士学历。历任加拿大永明金融蒙特利尔分部理财顾问、加 拿大帝国商业银行多伦多分部基金管理专员、国金证券上海承销保荐分公司投行项目经理。 ...
瑞康医药董秘解除留置;智翔金泰启动GR1802注射液过敏性鼻炎III期临床|医药早参
Mei Ri Jing Ji Xin Wen· 2025-08-13 23:33
Group 1 - Ruikang Pharmaceutical's executive Li Zhe has had his detention changed to a notice of investigation, indicating a shift in the investigation phase [1] - The change from detention to a notice of investigation suggests a reduced level of coercion, highlighting the importance of internal control and compliance systems in listed companies [1] Group 2 - Zhixiang Jintai has initiated a Phase III clinical trial for GR1802 injection for allergic rhinitis, following communication with the National Medical Products Administration [2] - GR1802 is slightly behind in clinical progress compared to two other approved drugs targeting the same indication, but successful commercialization could lead to competition with Dupilumab [2] Group 3 - Rongchang Biopharmaceutical's innovative drug RC18 (Taitaxip) for primary Sjögren's syndrome has met its primary endpoint in Phase III clinical trials, marking a potential first in the global market for this indication [3] - If approved, this drug could provide a breakthrough treatment for millions of patients in China and strengthen Rongchang's position in the autoimmune field [3] Group 4 - Hengrui Medicine's SHR-A2102, a targeted antibody-drug conjugate (ADC) for Nectin-4, has received approval for clinical trials in combination with Atezolizumab for recurrent/metastatic head and neck squamous cell carcinoma [4] - There is currently only one similar product on the market, Padcev, which is projected to generate $1.949 billion in sales in 2024, indicating significant market potential for this target [4] Group 5 - BeiGene has launched the first domestic Phase III clinical trial for subcutaneous Tislelizumab, a PD-1 inhibitor, for use in combination with chemotherapy for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [5] - The subcutaneous formulation is becoming a competitive area for PD-1/PD-L1 inhibitors, with three other subcutaneous PD-1/L1 products already approved globally [5]
8月13日晚间重要公告一览
Xi Niu Cai Jing· 2025-08-13 10:20
Group 1 - Kaizhong Precision plans to invest up to 250 million yuan to establish a subsidiary and build a production base in Thailand, focusing on overseas connector and precision component business [1] - Longbo Technology reported a 60.18% year-on-year increase in net profit for the first half of 2025, with revenue of 122 million yuan, up 18.03% [2] - Dingyang Technology achieved a net profit of 76.88 million yuan in the first half of 2025, a year-on-year increase of 31.54%, with revenue of 279 million yuan, up 24.61% [4] Group 2 - Heng Rui Pharmaceutical received approval for clinical trials of two drugs, SHR-A2102 and Adebeli monoclonal antibody injection [6] - Maolai Optical plans to use up to 100 million yuan of idle funds for entrusted wealth management to improve fund utilization efficiency [8] - Shiji Information signed a major contract with MGM Grand, providing a next-generation cloud-based hotel information management system [7] Group 3 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 4 - Aolaide expects a net profit decrease of 68.41% to 72.77% for the first half of 2025, with revenue projected between 270 million and 290 million yuan [12] - Feilong Co. used 111 million yuan of idle funds for cash management through structured deposit products [13] - Anhui Construction won two major projects with a total investment exceeding 6.6 billion yuan [15] Group 5 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 6 - China Medical's subsidiary received approval for the listing of fumaric acid volnora raw materials [20] - Huayuan Vaccine's subsidiary received approval for clinical trials of Hib vaccine [29] - Ganfeng Lithium plans to integrate lithium salt lake projects in Argentina and provide financial support of up to 130 million USD [41]
医药商业板块8月13日跌0.01%,华人健康领跌,主力资金净流入3373.55万元
| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301408 | 华人健康 | 15.11 | -1.76% | 17.96万 | 2.71亿 | | 300937 | 药易购 | 30.05 | -1.60% | 4.53万 | 1.36亿 | | 301015 | 百洋医药 | 25.98 | -1.55% | 29.18万 | 7.77亿 | | 600272 | 开开实业 | 13.87 | -1.42% | 6.94万 | 9642.32万 | | 301126 | 达嘉维康 | 13.25 | -1.41% | 14.39万 | 1.91亿 | | 603122 | 合富中国 | 7.23 | -1.36% | 6.01万 | 4356.44万 | | 002589 | 瑞康医药 | 3.05 | -1.29% | 43.86万 | 1.34亿 | | 301017 | 款玉平民 | 13.20 | -0.98% | 4.94万 | 6532.05万 | | 605266 | 健之佳 ...
瑞康医药集团股份有限公司 关于公司董事、董事会秘书及副总裁解除留置并变更为责令候查的公告
登录新浪财经APP 搜索【信披】查看更多考评等级 公司指定的信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资 讯网(http://www.cninfo.com.cn),公司所有信息均以在上述指定媒体刊登的信息为准。 敬请广大投资者理性投资,注意投资风险。 特此公告。 瑞康医药集团股份有限公司 证券代码:002589 证券简称:瑞康医药 公告编号:2025-040 瑞康医药集团股份有限公司 关于公司董事、董事会秘书及副总裁解除留置并变更为责令候查的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记载、误导性陈述或重大遗 漏。 瑞康医药集团股份有限公司(以下简称"公司")于2025年7月3日披露了《关于公司董事、董事会秘书及 副总裁被采取留置措施的公告》(公告编号:2025-037),公司董事、董事会秘书及副总裁李喆先生被 实施留置措施。 公司于2025年8月12日收到济南市济阳区监察委员会签发的《变更留置通知书》,济南市济阳区监察委 员会已解除对李喆先生的留置措施,变更为责令候查措施。目前公司生产经营情况正常,李喆先生能够 正常履行董事、董事会秘书及副总裁 ...
上市公司动态 | 中国联通半年营收破2000亿;贵州茅台净利增8.89%,称有利因素强于不利因素
Sou Hu Cai Jing· 2025-08-12 16:43
Group 1: China Unicom - Company revenue exceeded RMB 200 billion in the first half of the year, with a total profit of RMB 17.7 billion, representing a year-on-year increase of 5.2% [1] - Internet communication revenue reached RMB 131.9 billion, while intelligent network revenue amounted to RMB 45.4 billion, accounting for 26% of total revenue [1] - The number of connected users surpassed 1.2 billion, with mobile and broadband users increasing by over 11 million, reaching a total of 480 million [1] Group 2: Kweichow Moutai - The net profit for the first half of the year increased by 8.89%, with favorable factors outweighing unfavorable ones [2] Group 3: Shuanghui Development - The company reported a total meat product export volume of 1.57 million tons, a year-on-year increase of 3.67%, and total revenue of RMB 28.5 billion, up 3.00% [4] - The total profit decreased by 2.36%, while the net profit attributable to shareholders rose by 1.17% due to improved profitability in tax-exempt businesses [4] Group 4: Pengding Holdings - The company achieved a revenue of RMB 16.375 billion, a year-on-year increase of 24.75%, and a net profit of RMB 1.233 billion, up 57.22% [6] - The increase in revenue was attributed to a rise in customer orders [6] Group 5: Jinlongyu - The company reported a net profit increase of 60.07%, with revenue reaching RMB 115.68 billion, up from RMB 109.48 billion [9] - The growth in revenue was driven by increased sales of kitchen foods, feed raw materials, and oil technology products [9] Group 6: Other Companies - Zhenray Technology reported a turnaround in net profit due to significant growth in main business revenue [12] - Zhongke Sanhuan achieved a net profit increase of 160.82%, despite a revenue decline of 11.17% [16]
金橙子拟收购萨米特55%股权;瑞康医药副总裁李喆解除留置;*ST华微无法在责令改正期限内完成整改|公告精选
Mei Ri Jing Ji Xin Wen· 2025-08-12 14:55
Mergers and Acquisitions - Jin Chengzi plans to issue shares and pay cash to acquire 55% stake in Samit from eight parties including Wang Yongyang and Huang Meng, while also raising supporting funds [1] - Quzhou Development intends to purchase 95.46% of Xian Dao Electronic Technology Co., Ltd. through share issuance and will raise supporting funds [2] Performance Disclosure - Zhuyue Group reported a net profit of 585 million yuan for the first half of 2025, representing a year-on-year increase of 57.83%, with total revenue of 10.412 billion yuan, up 14.89% [3] - Zhenlei Technology announced a net profit of 62.32 million yuan for the first half of 2025, marking a significant year-on-year growth of 1006.99%, with revenue of 205 million yuan, up 73.64% [4] Shareholding Changes - Baichuan Co., Ltd. major shareholder Zheng Tiejiang plans to reduce his stake by up to 3%, equivalent to 17.83 million shares, from September 4 to December 3, 2025, due to personal financial needs [5] - Taiping Bird's shareholder Chen Hongchao intends to reduce his stake by no more than 3%, or 14.13 million shares, from August 19 to November 18, 2025, also for personal financial reasons [6] - Kanghua Biology's shareholder Chuanfa Selected No. 3 plans to reduce his stake by up to 3%, or 389,840 shares, within three months from the disclosure date [7] Risk Matters - *ST Huamei announced it failed to rectify fund occupation issues within the mandated period, leading to a suspension of its stock starting August 13, 2025, with potential delisting risks if not resolved within two months [8] - Ruikang Pharmaceutical reported that its director and board secretary Li Zhe had his detention lifted and changed to a warning measure, with normal business operations continuing [9]
瑞康医药董事、董事会秘书及副总裁李喆解除留置并变更为责令候查
Bei Jing Shang Bao· 2025-08-12 13:16
北京商报讯(记者 丁宁)8月12日晚间,瑞康医药(002589)发布公告称,公司于8月12日收到济南市 济阳区监察委员会签发的《变更留置通知书》,济南市济阳区监察委员会已解除对公司董事、董事会秘 书及副总裁李喆的留置措施,变更为责令候查措施。目前公司生产经营情况正常,李喆能够正常履行董 事、董事会秘书及副总裁职责。 ...